VALBIOTIS (EPA:ALVAL) | WebDisclosure

Basculer en Français

9480	Companies
185535	Keywords
117927	Articles
99378	Press releases

Home
Companies
VALBIOTIS

PRESS RELEASE

published on 01/30/2025 at 17:40, 10 months 6 days ago

VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
Valbiotis announces the market launch of Valbiotis®PRO Metabolic Health (Totum•63) in France on February 3rd, providing a natural, plant-based solution for metabolic diseases

Valbiotis Metabolic Diseases Metabolic Health Dietary Supplement TOTUM•63
BRIEF

published on 01/21/2025 at 17:45, 10 months 15 days ago

Valbiotis présente ses objectifs stratégiques et financiers à horizon 2030

Objectifs Financiers Valbiotis Ventes Internationales Objectifs 2030 Cardiométabolique
BRIEF

published on 01/21/2025 at 17:45, 10 months 15 days ago

Valbiotis Outlines 2030 Strategic and Financial Targets

Financial Targets Valbiotis International Sales 2030 Goals Cardiometabolic
PRESS RELEASE

published on 01/21/2025 at 17:40, 10 months 15 days ago

VALBIOTIS SA: Valbiotis dévoile ses ambitions stratégiques et financières à horizon 2030
Valbiotis dévoile ses ambitions stratégiques et financières à horizon 2030 avec trois produits pour la prise en charge des troubles cardio-métaboliques sur le marché en France dès 2025

Commercialisation Valbiotis Ambitions Stratégiques Financières Cardio-métaboliques
PRESS RELEASE

published on 01/21/2025 at 17:40, 10 months 15 days ago

VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
Valbiotis unveils its strategic and financial goals for 2030, focusing on product releases, turnover targets, and international sales expansion. Detailed roadmap and value proposition presented

Valbiotis Strategic Goals International Sales Financial Goals Product Releases
BRIEF

published on 01/14/2025 at 17:49, 10 months 22 days ago

Valbiotis Announces Success in HEART II Study on Lipidrive

Valbiotis Lipidrive Hypercholesterolemia HEART II Study LDL Cholesterol
BRIEF

published on 01/14/2025 at 17:49, 10 months 22 days ago

Valbiotis annonce le succès de l'étude HEART II sur Lipidrive

Valbiotis Cholestérol LDL Hypercholestérolémie Lipidrive Étude HEART II
PRESS RELEASE

published on 01/14/2025 at 17:45, 10 months 22 days ago

VALBIOTIS SA: Valbiotis annonce le large succès de l’étude clinique de phase II/III HEART II sur LIPIDRIVE
Valbiotis annonce le succès de l'étude clinique de phase II/III HEART II sur Lipidrive. Efficacité prouvée sur la réduction du LDL Cholestérol chez individus avec hypercholestérolémie légère à modérée

Valbiotis Étude Clinique Santé Cardiovasculaire Hypercholestérolémie LDL Cholesterol
PRESS RELEASE

published on 01/14/2025 at 17:44, 10 months 22 days ago

VALBIOTIS SA: Valbiotis annonce le large succès de l’étude clinique de phase II/III HEART II sur LIPIDRIVE
Valbiotis annonce le large succès de l'étude clinique de phase II/III HEART II sur LIPIDRIVE, démontrant l'efficacité sur la réduction du LDL Cholestérol. L'étude confirme l'approche scientifique innovante de Valbiotis

Valbiotis Santé Efficacité Étude Clinique LDL Cholesterol
PRESS RELEASE

published on 01/14/2025 at 17:44, 10 months 22 days ago

VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
Valbiotis announces success of phase II/III HEART II study on LIPIDRIVE, proving efficacy in reducing LDL cholesterol for mild to moderate hypercholesterolemia. Study validates safety & compliance of Lipidrive

Valbiotis Lipidrive Hypercholesterolemia HEART II Study LDL Cholesterol

Accesswire

Published on 12/05/2025 at 19:50, 20 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 50 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 25 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 50 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 2 hours 10 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 12 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 1 hour 44 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 1 hour 55 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours 19 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 24 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours 52 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 52 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 12 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE